Tag: BriaCell Therapeutics Corp.
May 28, 2019
BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast... May 17, 2019
Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 1,698,000 common shares (the “Shares”) of BriaCell Therapeutics... May 13, 2019
BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders
BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that... April 23, 2019
BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast... April 15, 2019
Successful BioPharma Startups Focus on the Science
BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF) was featured in an article by BioPharm International on process development in biopharma startups. April 3, 2019
BriaCell’s Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced early... April 2, 2019